Bing Yan, Chen Meng, Mi Lu, Mu Xian, Xiaomo Wang, Yuzhoujia Deng, Jing Wang, Zhen Chen, Luo Zhang, Chengshuo Wang
{"title":"Integrated-omics endotyping of patients with chronic rhinosinusitis with nasal polyps and their response to glucocorticoid therapy.","authors":"Bing Yan, Chen Meng, Mi Lu, Mu Xian, Xiaomo Wang, Yuzhoujia Deng, Jing Wang, Zhen Chen, Luo Zhang, Chengshuo Wang","doi":"10.1016/j.jaci.2026.07.029","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Integrated omics approaches provide deeper insights into disease heterogeneity, but combined host immune and nasal microbiota profiles in chronic rhinosinusitis with nasal polyps (CRSwNP) remain poorly characterized.</p><p><strong>Objective: </strong>This study aimed to identify biologically distinct CRSwNP endotypes by integrating transcriptomic and microbiota data from nasal brushings and to assess responses to corticosteroid therapy across these endotypes.</p><p><strong>Methods: </strong>Baseline transcriptomic and microbiota data from the multicenter COMPASS cohort (ClinicalTrials.gov registration: NCT05598424) were integrated using similarity network fusion and hierarchical clustering. Differential gene expression and bacterial genus abundance analyses were performed to characterize each endotype. In the COMPASS cohort, patients with CRSwNP who had a bilateral nasal polyp score (NPS) ≥ 4 points were enrolled and received 4 weeks of intranasal corticosteroid (INCS) treatment. Those whose NPS remained ≥4 after INCS treatment received a 2-week course of add-on systemic corticosteroid (SCS) therapy. Response rates were compared across endotypes using χ<sup>2</sup> or Fisher's exact tests.</p><p><strong>Results: </strong>Among 132 patients from 20 hospitals in China, four endotypes were identified: one non-type 2 inflammatory endotype (Cluster A) and three type 2 inflammatory endotypes distinguished by microbiota composition: a Corynebacterium-dominated profile (Cluster B), a Staphylococcus-dominated profile (Cluster C), and a polymicrobial profile (Cluster D). Among patients receiving add-on SCS therapy, Cluster C showed the highest observed response rate (94.1%), followed by Cluster D (72.7%), Cluster B (62.5%), and Cluster A (56.7%).</p><p><strong>Conclusion: </strong>Integrated transcriptome and microbiota analysis identified four CRSwNP endotypes with distinct immune-microbial signatures and variable corticosteroid responsiveness, supporting the potential for endotype-driven precision therapy in CRSwNP.</p>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":11.7000,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaci.2026.07.029","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Integrated omics approaches provide deeper insights into disease heterogeneity, but combined host immune and nasal microbiota profiles in chronic rhinosinusitis with nasal polyps (CRSwNP) remain poorly characterized.
Objective: This study aimed to identify biologically distinct CRSwNP endotypes by integrating transcriptomic and microbiota data from nasal brushings and to assess responses to corticosteroid therapy across these endotypes.
Methods: Baseline transcriptomic and microbiota data from the multicenter COMPASS cohort (ClinicalTrials.gov registration: NCT05598424) were integrated using similarity network fusion and hierarchical clustering. Differential gene expression and bacterial genus abundance analyses were performed to characterize each endotype. In the COMPASS cohort, patients with CRSwNP who had a bilateral nasal polyp score (NPS) ≥ 4 points were enrolled and received 4 weeks of intranasal corticosteroid (INCS) treatment. Those whose NPS remained ≥4 after INCS treatment received a 2-week course of add-on systemic corticosteroid (SCS) therapy. Response rates were compared across endotypes using χ2 or Fisher's exact tests.
Results: Among 132 patients from 20 hospitals in China, four endotypes were identified: one non-type 2 inflammatory endotype (Cluster A) and three type 2 inflammatory endotypes distinguished by microbiota composition: a Corynebacterium-dominated profile (Cluster B), a Staphylococcus-dominated profile (Cluster C), and a polymicrobial profile (Cluster D). Among patients receiving add-on SCS therapy, Cluster C showed the highest observed response rate (94.1%), followed by Cluster D (72.7%), Cluster B (62.5%), and Cluster A (56.7%).
Conclusion: Integrated transcriptome and microbiota analysis identified four CRSwNP endotypes with distinct immune-microbial signatures and variable corticosteroid responsiveness, supporting the potential for endotype-driven precision therapy in CRSwNP.
期刊介绍：
The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
